Official Title

Melatonin for Huntington's Disease (HD) Gene Carriers With HD Related Sleep Disturbance - a Pilot Study
  • Phase

    N/A
  • Study Type

    Interventional
  • Status

    Recruiting
  • Intervention/Treatment

    Melatonin ...
  • Study Participants

    20
The purpose of the study is to evaluate the efficacy of exogenous melatonin in improving sleep quality in HD gene carriers.
Study Started
Jan 22
2021
Primary Completion
Jan 01
2023
Anticipated
Study Completion
Jan 01
2023
Anticipated
Last Update
May 25
2022

Dietary Supplement Melatonin

Participants will receive melatonin 5 mg once a day (30 min prior to bedtime) for four weeks, followed by one-week washout before crossing-over.

Other Placebo

Participants will receive placebo once a day (30 min prior to bedtime) for four weeks, followed by one-week washout before crossing-over.

Melatonin Experimental

Placebo Placebo Comparator

Criteria

Inclusion Criteria:

Verified HD mutation carriers.
Patients who report sleep disturbance as measured by a score ≥5 on the Pittsburgh Sleep Quality Index (PSQI);
Stable concomitant medication (no change of medication during last 30 days prior to inclusion);
Written informed consent by prospective study participant before conduct of any trial-related procedure;
Participant must be able to make an informed decision of whether or not to participate in the study.

Exclusion Criteria:

Pregnant or nursing women;
Woman of childbearing potential, not using highly effective methods of contraception such as oral, topical or injected contraception, intrauterine device (IUD), contraceptive vaginal ring, or double barrier method such as diaphragm and condom with spermicide) or not surgically sterile (via hysterectomy, ovariectomy or bilateral tubal ligation) or not at least one year post menopausal;
Presence of any medically not controllable disease (e.g. uncontrolled arterial hypertension or diabetes mellitus);
Use of benzodiazepines, sedating antidepressants (mirtazapine or trazodone) or sedating antipsychotics (olanzapine and quetiapine) in the previous four weeks;
Severe cognitive disorders defined as a score < 18 on the MOCA;
Participation in another investigative drug trial within 2 months;
Subjects who are unlikely to be compliant and attend scheduled clinic visits as required as determined by the Investigator.
No Results Posted